Artificial intelligence in unveiling herbal remedies for cancer:
Advances and applications
Authors
- Bargale Sushant Sukumar
Department of Swasthavritta and Yoga, Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital, Hassan, Karnataka, India
https://orcid.org/0000-0002-9780-9070 - Shashirekha H K
Department of Samhita Sanskrit, Banaras Hindu University, Varanasi, Uttar Pradesh, India
https://orcid.org/0000-0002-1421-2886 - Amarnath H K
Department of Shalakya Tantra, Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital, Hassan, Karnataka, India
https://orcid.org/0000-0003-0377-8435 - Neha Gadgil
Department of Kriya Sharir, Sri Lal Bahadur Shastri Smarak Rajakiya Ayurvedic Mahavidyalaya, Handia, Prayagraj, Uttar Pradesh, India
https://orcid.org/0000-0003-1127-5934 - Akshar Kulkarni
Department of Samhita Siddhanta, Parul Institute of Ayurved, Parul University, Vadodara, Gujarat, India
https://orcid.org/0000-0002-9382-5591 - Shipra
Department of Prasuti Tantra and Striroga, Sri Lal Bahadur Shastri Smarak Rajakiya Ayurvedic Mahavidyalaya, Handia, Prayagraj, Uttar Pradesh, India
https://orcid.org/0009-0002-4417-2042 - Harshal Tare
Department of Pharmacognosy, Sharadchandra Pawar College of Pharmacy, Pune, Maharashtra, India
https://orcid.org/0000-0002-4404-5396
DOI:
https://doi.org/10.3329/bsmmuj.v18i1.76190Keywords
Downloads
Correspondence
Publication history
Handling editor
Reviewers
Funding
Ethical approval
Trial registration number
Copyright
Published by Bangabandhu Sheikh
Mujib Medical University
For the literature search in this commentary, specific inclusion and exclusion criteria were applied to ensure relevant studies were selected. Inclusion criteria included: (1) studies focused on the use of AI techniques (such as machine learning, deep learning, and natural language processing) in discovering herbal remedies for cancer. Exclusion criteria included: (1) studies not related to AI. AI plays a crucial role in personalized herbal treatments by integrating patient data (genetic, medical, lifestyle) to customize therapies, using predictive analytics to forecast responses and adjust treatments based on feedback for optimal outcomes and minimized side effects.[3]
AI implementation in herbal medicine faces several technical challenges. Data quality and accessibility issues include gaps in critical information, which limit prediction accuracy, and difficulties in integrating diverse data sources due to varying formats and standards. Algorithm limitations arise from models trained on specific datasets that may not generalize well to new or unseen data, particularly for diverse herbal compounds and patient populations. The complexity of herbal mixtures, with multiple active constituents, adds another challenge, as AI models may struggle to capture their synergistic effects. Additionally, high computational demands for advanced AI models can be a barrier for smaller research labs or organizations lacking access to powerful computing resources.[4]
AI techniques have significantly enhanced herbal drug discovery for cancer, with machine learning models identifying promising compounds like curcumin, paclitaxel, camptothecin, resveratrol and Epigallocatechin-3-gallate. Deep learning and natural language processing have accelerated drug-target interaction predictions, extracting key insights from databases with published studies. Advancements like transfer learning and Graph Neural Networks have optimized herbal compound synergy, increasing the accuracy of compound-target interaction models by 15%. Platforms like Atomwise have improved the success rate for compounds with anticancer potential by 30%, while DeepChem has significantly improved the discovery methodology (Table 1).[5]
Application | Description | AI techniques used | Benefits | Relevance to drug discovery |
Identification of target | AI analyzes extensive datasets to detect proteins, genes, or pathways affecting disease mechanisms, aiding in identifying promising targets. | Machine learning, data mining | Focuses research on the most promising targets | Target identification is crucial for the success of drug discovery, helping streamline the search for effective treatments. |
Substance testing | AI optimizes drug screening by predicting the most effective compounds, reducing the need for extensive experimental testing. | Predictive models, convolutional neural networks | Reduces experimental workload, accelerates discovery process | AI’s predictive capabilities enhance efficiency by narrowing down the best candidates, saving time and resources. |
Predictive modelling | AI-driven models predict ADMETa properties of drug candidates, helping assess potential effectiveness and safety before experimental validation. | Statistical techniques, machine learning | Expedites and reduces costs of drug development | Predictive modelling reduces failure rates in clinical trials by assessing the safety and efficacy of drugs early in the process. |
Drug repurposing | AI finds new therapeutic uses for approved drugs by uncovering correlations between drugs and diseases. | Data analysis, natural language processing | Accelerates development using existing safety and efficacy data | Drug repurposing is a cost-effective strategy to quickly find new treatments, leveraging existing drugs for new indications. |
aADMET indicates absorption, distribution, metabolism, elimination and toxicity |
It can be concluded that AI has the capacity to enhance accuracy, expedite the discovery and optimise clinical studies in order to revolutionise the antineoplastic treatments with special reference to bioactive molecules.
Categories | Number (%) |
Sex |
|
Male | 36 (60.0) |
Female | 24 (40.0) |
Age in yearsa | 8.8 (4.2) |
Education |
|
Pre-school | 20 (33.3) |
Elementary school | 24 (40.0) |
Junior high school | 16 (26.7) |
Cancer diagnoses |
|
Acute lymphoblastic leukemia | 33 (55) |
Retinoblastoma | 5 (8.3) |
Acute myeloid leukemia | 4 (6.7) |
Non-Hodgkins lymphoma | 4 (6.7) |
Osteosarcoma | 3 (5) |
Hepatoblastoma | 2 (3.3) |
Lymphoma | 2 (3.3) |
Neuroblastoma | 2 (3.3) |
Medulloblastoma | 1 (1.7) |
Neurofibroma | 1 (1.7) |
Ovarian tumour | 1 (1.7) |
Pancreatic cancer | 1 (1.7) |
Rhabdomyosarcoma | 1 (1.7) |
aMean (standard deviation) |
Categories | Number (%) |
Sex |
|
Male | 36 (60.0) |
Female | 24 (40.0) |
Age in yearsa | 8.8 (4.2) |
Education |
|
Pre-school | 20 (33.3) |
Elementary school | 24 (40.0) |
Junior high school | 16 (26.7) |
Cancer diagnoses |
|
Acute lymphoblastic leukemia | 33 (55) |
Retinoblastoma | 5 (8.3) |
Acute myeloid leukemia | 4 (6.7) |
Non-Hodgkins lymphoma | 4 (6.7) |
Osteosarcoma | 3 (5) |
Hepatoblastoma | 2 (3.3) |
Lymphoma | 2 (3.3) |
Neuroblastoma | 2 (3.3) |
Medulloblastoma | 1 (1.7) |
Neurofibroma | 1 (1.7) |
Ovarian tumour | 1 (1.7) |
Pancreatic cancer | 1 (1.7) |
Rhabdomyosarcoma | 1 (1.7) |
aMean (standard deviation) |